<DOC>
	<DOCNO>NCT02042001</DOCNO>
	<brief_summary>Despite long-term use clinical practice , chronic treatment efavirenz ( EFV ) associate persistent central nervous system symptom mild even asymptomatic neurocognitive impairment . Whether switch rilpivirine ( RPV ) contain regimen beneficial among patient experience mild asymptomatic neurocognitive/neuropsychiatric adverse event EFV explore yet . The propose pilot study examine whether switch EFV-based regimen single tablet regimen TDF/FTC/RPV associate neurocognitive/neuropsychiatric improvement among HIV-infected patient mild/asymptomatic neurocognitive impairment neuropsychiatric symptom EFV-containing antiretroviral treatment . Patients stable treatment EFV , confirm HIV-1 RNA viral load &lt; 50 copies/mL alter score depression , quality sleep anxiety test and/or alteration 1 domain assessed neuropsychological assessment , randomize immediate defer ( 12 week ) switch TDF/FTC/RPV . Neurocognitive neuropsychiatric test repeat 12 24 week follow-up variation compare group .</brief_summary>
	<brief_title>Switching From Efavirenz/Atripla Rilpivirine Among Patients With Neurocognitive Neuropsychological Side Effects</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Age ≥18 year old ability sign inform consent Continuative treatment EFV combination TDF/FTC abacavir/lamivudine ( ABC/3TC ) ≥180 day HIV1 RNA viral load &lt; 50 copies/mL two consecutive determination ( include screen ) No history treatment failure and/or evidence mutation associate resistance NRTI NNRTI No contraindication treatment study drug Any one following condition : ( ) Altered score depression , quality sleep anxiety test ( ii ) Alteration 1 domain assessed neuropsychological assessment Ongoing treatment predictable need treatment proton pump inhibitor New AIDS define condition diagnose within 21 day prior screen Previous diagnosis AIDS dementia complex Current alcohol substance dependence Major psychiatric disorder Decompensated cirrhosis Plasma creatinine &gt; 1.2 mg/dl estimate glomerular filtration rate &lt; 60 ml/min ( MDRD formula ) AST , ALT plasma bilirubin &gt; 3 time upper limit normal Any clinical condition prior therapy would make subject unsuitable study unable comply dosing/food requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>